|Home | About | Journals | Submit | Contact Us | Français|
The atypical MAP kinases ERK3 and ERK4 are activated by phosphorylation of a serine residue lying within the activation loop signature sequence S-E-G. However, the regulation of ERK3 and ERK4 phosphorylation and activity is poorly understood. Here we report that the inducible nuclear dual-specificity MAP kinase phosphatase (MKP) DUSP2, a known regulator of the ERK and p38 MAPKs, is unique amongst the MKP family in being able to bind to both ERK3 and ERK4. This interaction is mediated by a conserved common docking (CD) domain within the carboxyl-terminal domains of ERK3 and ERK4 and the conserved kinase interaction motif (KIM) located within the non-catalytic amino terminus of DUSP2. This interaction is direct and results in the dephosphorylation of ERK3 and ERK4 and the stabilization of DUSP2. In the case of ERK4 its ability to stabilize DUSP2 requires its kinase activity. Finally, we demonstrate that expression of DUSP2 inhibits ERK3 and ERK4-mediated activation of its downstream substrate MK5. We conclude that the activity of DUSP2 is not restricted to the classical MAPK pathways and that DUSP2 can also regulate the atypical ERK3/4-MK5 signalling pathway in mammalian cells.
ERK3 and ERK4 are members of the so-called “atypical” family of mitogen activated protein kinases (MAPKs), which also includes ERK7/8 and Nemo Like Kinase (NLK)1. One major difference between the ERK3 and ERK4 and classical MAP kinases such as ERK1/2, p38 isoforms, and c-Jun N-terminal kinases (JNKs), is the substitution of the conserved T-X-Y motif within the activation loop by a single phospho-acceptor residue within an S-E-G motif2,3. Phosphorylation of the serine residue within this motif is instrumental for the ability of both ERK3 and ERK4 to interact with and activate MAPK-activated protein kinase 5 (MK5 or PRAK), the only well-characterized physiological substrate of these atypical MAPKs. The regulation of both ERK3 and ERK4 activity is poorly understood, as is the physiological context in which activation can occur. Recently, members of the class I p21-activated kinases (PAKS) were shown to mediate robust phosphorylation of the S-E-G motif resulting in enzymatic activation of both ERK3 and ERK4 and downstream activation of MK5/PRAK4,5. Interestingly, phosphorylation of the S-E-G motif in ERK4 is also substantially increased on binding to MK5 but this does not require MK5 kinase activity, indicating that MK5 either facilitates the activity of an ERK4 kinase or prevents the dephosphorylation and inactivation of ERK46.
The classical MAPKs interact with both upstream activators, regulatory proteins and substrates through conserved clusters of acidic amino acids, which constitute the so called “common docking” (CD) domain7. In contrast, we recently reported that the interaction of both ERK3 and ERK4 with MK5 is mediated by a novel (FRIEDE) MAPK binding motif found in the C-terminal extension of both kinases8. However, the observation that both ERK3 and ERK4 contain a conserved consensus sequence motif indicative of a functional CD domain strongly suggests that these kinases may utilize this binding site to interact with as yet unidentified regulatory proteins.
Prominent amongst candidate regulatory proteins, which interact with MAPKs via the CD domain, are a family of ten dual-specificity MAPK phosphatases (MKPs or DUSPs)9. These phosphatases act in direct opposition to the upstream dual specificity MAPK kinase (MKK or MEK) by dephosphorylating both the tyrosine and threonine residues within the T-X-Y motif, thus inactivating the MAPK. MKPs interact with the cognate CD domain in MAPKs via a conserved kinase interaction motif (KIM), which is located within the amino-terminal non-catalytic domain of the phosphatase. It is thought that variations in the modular sequence of this KIM combined with the presence of either nuclear localisation signals (NLS) or nuclear export signals (NES) determine the differential substrate specificity and subcellular localisation of the MKPs10.
Here we have used a yeast 2-hybrid assay to screen all ten members of the mammalian MKP family for the ability to interact with ERK3 and 4 and find that these kinases specifically interact with DUSP2, a phosphatase previously identified as a regulator of signalling through both the ERK and p38 MAPK pathways11,12,13. The interaction of DUSP2 with both ERK3 and ERK4 in yeast and mammalian cells required a functional KIM and was abolished by mutation of the CD domain in both ERK3 and ERK4. Furthermore, the formation of a complex between ERK4 and DUSP2 led to an increase in the stability of DUSP2, which was at least in part dependent on the catalytic activity of ERK4. Importantly, the expression of wild-type DUSP2 led to efficient dephosphorylation of the phospho-acceptor site within the S-E-G motif of both ERK3 and 4 in vivo. Finally, we demonstrate that DUSP2 inhibits ERK3 and ERK4 mediated activation of MK5. We conclude that the activity of DUSP2 is not restricted to the classical MAPK pathways and that uniquely amongst this family of enzymes DUSP2 is also a physiological regulator of the atypical ERK3/4 MAPKs in mammalian cells.
As a first step in determining if the atypical MAPKs ERK3 and ERK4 might be subject to regulatory dephosphorylation we tested a number of human dual-specificity MAPK phosphatases for their ability to interact with these atypical MAPKs using the yeast 2-hybrid assay. These assays revealed that, in addition to its well-characterized ability to interact with ERK2, DUSP2 was also able to interact with both ERK3 and ERK4. In contrast, the inducible nuclear MKP DUSP1/MKP-1, which can interact with ERK1/2, p38α and JNK114, did not bind to either ERK3 or ERK4. Nor did the cytoplasmic ERK1/2-specific MKP DUSP6/MKP-3 or either of the p38/JNK-specific MKPs DUSP10/MKP-5 or DUSP16/MKP-7 (Fig. 1a). In additional yeast 2-hybrid assays, no interactions were detected between ERK3 or ERK4 and the other 5 members of the MKP family15,16 and data not shown. The ability of DUSP2 to interact with ERK2, ERK3 and ERK4 was absolutely dependent on the integrity of the kinase interaction motif (KIM) located within the amino-terminal non-catalytic domain of the phosphatase as mutation of conserved arginine residues within this region abolished the interaction. In contrast, binding to ERK2, ERK3, and ERK4 do not require DUSP2 catalytic activity, as a mutation of the active site cysteine to serine (C257S), did not affect its ability to interact with all three MAPKs (Fig. 1b). The requirement for the KIM in DUSP2 suggests that these interactions are mediated via the conserved “common docking” (CD) domain of these MAPKs. This is confirmed, as mutants in which this docking site is disrupted by mutation of a conserved aspartic acid residue (D319N, in ERK2, D324N in ERK3 and D320N in ERK4) abolishes the ability of DUSP2 to bind to ERK2 and ERK3 and greatly reduces the interaction of DUSP2 with ERK4 (Fig. 1c).
To show that these interactions are direct, GST pull-down assays were performed using purified recombinant ERK3 and ERK4 and a fusion between GST and the murine homologue of DUSP2. Both wild-type and a catalytically inactive (C261S) mutant of DUSP2 clearly interacted directly with both ERK3 and ERK4. In contrast, the KIM mutant of DUSP2 was completely unable to interact with either ERK3 or ERK4 (Fig. 2a and b).
ERK3 and ERK4 also formed complexes with wild-type and catalytically inactive DUSP2 when co-expressed in in HeLa cells (Fig. 2c and d). The inactive mutant (DUSP2CS) is used here to act as a potential substrate trap17. In both cases this interaction was lost when the KIM motif was mutated. We could also detect interaction between endogenous ERK3 and endogenous DUSP2 in Jurkat T-cells stimulated with PMA and OKT3 (Fig. 2e) indicating that the interactions are physiologically relevant. We can conclude that, unlike other dual-specificity MKPs, DUSP2 is able to interact with the atypical MAPKs ERK3 and ERK4 both in vitro and in mammalian cells.
Several dual-specificity MKPs exhibit catalytic activation on binding to their cognate MAPK substrates in vitro. Thus the activities of DUSP6/MKP-3 and DUSP1/MKP-1 towards the chromogenic substrate para-nitrophenyl phosphate (p-NPP) are significantly increased on addition of either recombinant ERK2 (DUSP6/MKP-3) or either ERK2, p38α, or JNK1 (DUSP1/MKP-1)14,18. This activation is due to allosteric rearrangement of residues within the active site of these enzymes on substrate binding and, in particular, on a conformational change, which places a conserved general acid residue in an optimal position for catalysis19. Catalytic activation has also been observed when DUSP2 is incubated in the presence of recombinant ERK220. We tested the ability of recombinant ERK2, ERK3, and ERK4 to activate recombinant murine DUSP2 in vitro. As previously reported, addition of ERK2 resulted in a significant increase in the rate of p-NPP hydrolysis by DUSP2 and this did not occur when the KIM motif was mutated (Fig. 3). In contrast, addition of recombinant ERK3 or ERK4 did not lead to any significant increase in DUSP2 activity, indicating that although both ERK3 and ERK4 can bind to DUSP2, this binding does not result in catalytic activation of the phosphatase.
To test the ability of DUSP2 to dephosphorylate ERK4 in mammalian cells, we co-expressed either wild-type DUSP2, DUSP1/MKP-1, or DUSP6/MKP-3 with a GFP fusion of a kinase deficient mutant of ERK4 (D168A) in HeLa cells. Kinase dead mutants of ERK4 (and ERK3, see below) were used in these experiments to prevent autophosphorylation of the activation loop reversing the cellular activity of the DUSP2 phosphatase during the immunoprecipitation procedure, which is carried out in buffers containing the phosphatase inhibitor sodium orthovanadate. ERK4 was then immunoprecipitated from cell lysates using an anti-GFP antibody and Western blots were performed using an antibody that specifically recognizes ERK4 when phosphorylated at S186 within the S-E-G motif. Expression of DUSP2 clearly caused a significant reduction in the phosphorylation of S186, while the expression of either DUSP1/MKP-1 or DUSP6/MKP-3 had no effect on this modification (Fig. 4a). The DUSP2-mediated dephosphorylation of ERK4 was strictly dependent on the intrinsic phosphatase activity as strong interaction, but no dephosphorylation, was seen upon coexpression of the catalytically inactive (S261) mutant of DUSP2 (DUSP2 CS) (Fig. 4b). ERK4 with a mutated common docking (CD) domain (ERK4D320N) was not dephosphorylated upon DUSP2 coexpression and DUSP2 with a mutated KIM domain did not dephosphorylate wild-type ERK4 (Fig. 4b). This strongly indicates that direct interaction between the two proteins is necessary for DUSP2-mediated ERK4 dephosphorylation. The same was observed when DUSP2 was coexpressed in HeLa cells with a kinase-inactive mutant of ERK3(D171A) (Fig. 4c). In contrast, neither a catalytically deficient nor a KIM mutant of DUSP2 was able to dephosphorylate ERK3. We conclude that DUSP2 is able to dephosphorylate both ERK3 and ERK4 when expressed in mammalian cells.
We recently discovered a novel sequence motif located within the L16 extension lying C-terminal to the CD domain in both ERK3 and ERK4. This “FRIEDE” motif is absolutely required for both ERK3 and ERK4 to bind to MK5/PRAK and a single isoleucine to lysine substitution (I334K in ERK3 and I330K in ERK4) totally abrogates binding, activation, and nuclear to cytoplasmic translocation of MK5 by both kinases8. To determine if this motif plays any role in the binding between either ERK3 or ERK4 and DUSP2 we co-expressed Myc-tagged ERK3 or ERK4, either wild-type, with the FRIEDE motif mutation or a mutation in the CD domain, together with inactive DUSP2 (DUSP2CS). Clearly both the wild-type and the FRIEDE mutant forms of ERK3 and ERK4 bind to DUSP2, while mutation of the CD domain completely abrogated the binding (Fig. 5a and b). We can conclude that the FRIEDE motifs and the CD domains function completely autonomously in the binding of both ERK3 and ERK4 to either their specific substrate MK5, or the regulatory protein phosphatase DUSP2 respectively.
Several studies have shown that dual-specificity phosphatases are able to influence the subcellular distribution of MAP kinases16,21. We have previously shown that ERK3 predominantly localizes to the cell nucleus whereas ERK4 localizes to the cytoplasm. However, both kinases are able to shuttle between the nucleus and the cytoplasm. To investigate if DUSP2 could affect the subcellular distribution of ERK3 and ERK4, we overexpressed EGFP-fusion proteins of either ERK3 or ERK4 alone or together with a catalytically inactive version of DUSP2. In agreement with a previous report13, ectopically expressed DUSP2CS is localized to the cell nucleus (Fig. 6a). Interestingly, upon co-expression of both ERK3 and ERK4, the phosphatase relocalises from the nucleus to the cytoplasm, and co-expression of ERK3 and DUSP2 led to a relocalization of both proteins from the nucleus to the cytoplasm. This is reminiscent of the effects of co-expressing ERK3 and ERK4 with its binding partner and substrate MK5, which also causes both proteins to relocalise to the cytoplasm22,23 In contrast, the localization of a phosphatase-inactive DUSP2 KIM mutant remained predominantly nuclear upon co-expression with either ERK3 or ERK4 (Fig. 6b and c). We conclude that KIM-dependent protein-protein interactions between DUSP2 and either ERK3 or ERK4 cause the redistribution of DUSP2 from nucleus to cytoplasm.
Many MKPs are relatively unstable proteins and their half-life can be modified by either site-specific phosphorylation or binding to their cognate substrates. For instance, DUSP1/MKP-1 is stabilized by ERK2-dependent phosphorylation of C-terminal residues, while both DUSP5 and DUSP6/MKP-3 are stabilized on binding to ERK224,25,26. To explore the relationship between DUSP2 stability and ERK4 we expressed DUSP2 either in the presence or absence of wild-type ERK4 and monitored the loss of the DUSP2 protein on addition of the protein synthesis inhibitor cycloheximide. DUSP2 levels declined rapidly following cycloheximide addition, indicating that the protein is highly unstable in vivo. However, co-expression of ERK4 significantly increased the half-life of DUSP2 (Fig. 7a). This was strictly dependent of the integrity of the KIM motif within DUSP2, as a KIM mutant was not stabilized on expression of ERK4 (Fig. 7b). Interestingly, a kinase dead mutant of ERK4 was not as efficient as wild-type ERK4 in stabilizing DUSP2 despite being expressed at similar levels, indicating that catalytic activity and possibly the phosphorylation of DUSP2 by ERK4 might play some role in increasing DUSP2 stability (Fig. 7d). Finally, only co-expression of wild-type ERK4 had a significant effect on DUSP2 stability as expression of either ERK2, p38α or JNK1 caused only a minor increase in the half-life of DUSP2 when compared with ERK4 (Fig. 7e). Co-expression of ERK3 did not give rise to similar increase in DUSP2 half-life (data not shown).
The best characterized protein substrate for the atypical MAPKs ERK3 and ERK4 is MK5 (PRAK)22,23,27,28. The activation of MK5 by ERK3 and ERK4 is mediated by phosphorylation of T182 within the activation loop of MK5 and this is dependent on specific interactions between ERK3/ERK4 and MK5 mediated by the FRIEDE motif within the C-terminal domain of these atypical MAPKs8. We have previously shown that phosphorylation of S186 within ERK4 is absolutely necessary for its ability to interact with, phosphorylate, and activate MK56. To determine the effects of DUSP2 on MK5 activation loop phosphorylation, an EGFP-MK5 fusion protein was co-expressed with myc-tagged wild-type ERK4 in the absence or presence of either wild-type DUSP2 or the KIM mutant of DUSP2. The cell lysates were analysed by Western blotting using a specific antibody that specifically recognises MK5 when phosphorylated on T182. As previously demonstrated, MK5 was phosphorylated on T182 upon co-expression of ERK4. However, coexpression of wild-type DUSP2, but not the KIM mutant of DUSP2 significantly reduced the levels of T182 phosphorylation (Fig. 8a and b). This strongly indicates that the ability of DUSP2 to dephosphorylate S186 within ERK4 results in disruption of its interaction with and subsequent activation of MK5 (Fig. 8a and b). Identical results were obtained when EGFP-MK5 was co-expressed with wild-type ERK3 and either wild-type or the KIM mutant of DUSP2 (Fig. 8c and d). Overall these results clearly indicate that DUSP2 is capable of negatively regulating signal transduction through the ERK3/4-MK5 pathway in mammalian cells.
The atypical MAP kinases ERK3 and ERK4 are unusual in that the signature activation motif T-X-Y, which is conserved in all classical MAPKs, is replaced by S-E-G in which the serine residue is the sole phospho-acceptor. Despite this difference, it is now clear that phosphorylation of S189 and S186 in ERK3 and ERK4, respectively, is both essential and sufficient for the ability of these kinases to interact with, phosphorylate, and activate their best characterised downstream substrate the MK5 (PRAK) protein kinase both in vitro and in vivo6,29. The fact that ERK3 and ERK4 require phosphorylation of a single serine residue dispenses with the requirement that the upstream activating kinase be a member of the MEK (or MKK) family of dual–specificity Thr/Tyr protein kinases. Indeed, where tested these enzymes have negligible activity towards the S-E-G motif in ERK3 in vitro30, suggesting that this signalling pathway may employ a non-canonical activation mechanism. This idea is supported by the recent finding that members of the class I p21-activated kinases (PAks) mediate robust phosphorylation of the S-E-G motif resulting in enzymatic activation of both ERK3 and ERK4 and downstream activation of MK5/PRAK in vivo4,5. Despite the emergence of this novel Pak1-ERK3/ERK4-MK5 signalling axis, many questions remain to be answered about the regulation of this atypical MAPK pathway. In particular, studies of the kinetics of ERK3/ERK4 phosphorylation have shown no particular correlation with any physiological agonists or stress conditions normally associated with MAPK pathway activation and the phosphorylation of S189 in ERK3 can persist in quiescent cells in the absence of growth factor stimulation29.
One important regulatory mechanism employed to control the activity of MAPKs is the regulated and specific dephosphorylation of the T-X-Y motif by a family of dual-specificity MAPK phosphatases9. Despite the non-canonical activation mechanism employed by these kinases the “common docking” (CD) domain that mediates protein-protein interactions between classical MAPKs and a range of downstream substrates and regulators is conserved in both ERK3 and ERK48. However, the interaction between both ERK3 and ERK4 and their substrate MK5 is mediated by the FRIEDE motif, a distinct and novel MAPK interaction site within the C-terminal domain of both kinases8. Given the importance of the CD domain in the interactions between classical MAPKs and regulatory phosphatases7 we screened the ten members of the dual-specificity MKP family for their ability to interact with ERK3 and ERK4 using the yeast 2-hybrid assay. This revealed that a single member of this family, DUSP2, was able to bind to ERK3 and ERK4 and that this interaction was absolutely dependent on the integrity of both the CD domain and the conserved kinase interaction motif (KIM) located within the amino terminal non-catalytic domain of DUSP2.
DUSP2 was originally characterised as a mitogen-inducible nuclear protein tyrosine phosphatase in T cells13 and subsequently shown to have catalytic activity towards both the classical ERK1/2 MAPKs and to a lesser extent the p38 stress-activated MAPKs11,12. Our results indicate that DUSP2 binds as strongly, if not more strongly, to both ERK3 and ERK4 compared to ERK2 in vitro. Moreover our experiments show that this interaction is direct and results in the efficient dephosphorylation of the serine phospho-acceptor residue within the activation loop of ERK3 and ERK4. Although binding to ERK2 results in a significant increase in the catalytic activity of DUSP2 in vitro, no such increase in activity is seen on incubation with either ERK3 or ERK4. However, although catalytic activation is a feature of several MKPs it is not a universal property of these proteins and several phosphatases including DUSP5 and DUSP10 are not activated on binding to their bona fide MAPK substrates9.
Several MKPs are relatively unstable proteins in vivo and their turnover is mediated by proteosomal degradation. In certain cases, such as DUSP1/MKP-1 and DUSP4/MKP-2 the interaction of the phosphatase with MAPK substrate results in phosphorylation of the former and a decrease in the rate of protein turnover. Interestingly, we found that the co-expression of ERK4 and DUSP2 increased the stability of the latter and that this stabilization was dependent on both the KIM motif in DUSP2 and on the catalytic activity of ERK4, a possible indication that the phosphorylation of DUSP2 might be involved in stabilisation of the protein. In support of the latter notion we have shown that wild-type ERK4 can phosphorylate DUSP2 in vitro and future studies will be aimed at identifying the relevant site(s) of modification and determining their influence on DUSP2 stability. Finally, we have clearly demonstrated that the expression of DUSP2 is capable of supressing the ERK3 or ERK4-dependent phosphorylation of MK5, indicating that DUSP2 may regulate the Pak-ERK3/ERK4-MK5 signalling axis.
Although DUSP2 can suppress ERK3 and ERK4 mediated activation of ectopically expressed MK5, we have not been able to detect any influence of DUSP2 expression on endogenous MK5 activity (data not shown). These experiments were performed using siRNA knockdown of DUSP2 in activated Jurkat T-cells were DUSP2 is readily induced in response to activation of the T-cell receptor and the endpoint assay was a change in MK5 activation loop phosphorylation assayed in while cell extracts by Western blotting. Our failure to see any changes in MK5 phosphorylation could be because DUSP2 is acting on a subpopulation of ERK3 perhaps in a discrete subcellular compartment. Furthermore, we and others have shown that co-expression of MK5 increases the phosphorylation of S189 and S186 in ERK3 and ERK4 respectively6,29, suggesting that perhaps the activation-loop of ERK3 and ERK4 is not accessible for dephosphorylation when complexed with MK5. Thus, DUSP2 may be important for the suppression of ERK3 (or ERK4) activity in respect of other as yet unidentified targets or may modulate kinase activity in certain subcellular compartments. Finally, there may be cell types where DUSP2 plays a more prominent role in the regulation of MK5 activation. However, so far we have been unable to identify other cell lines in which we can detect endogenous co-expression of ERK3/ERK4, DUSP2 and MK5.
In conclusion, our results strongly suggest that the atypical MAPKs ERK3 and ERK4 are bona fide substrates of DUSP2 and this represents a significant step forward in our understanding of these atypical MAPK signalling pathways. In addition, the discovery that DUSP2 can regulate ERK3 and ERK4 provides an additional tool with which to modulate the activities of these pathways in vivo. Finally, despite it being amongst the first of the dual-specificity MKPs to be identified in mammalian cells, the physiological function(s) of DUSP2 are rather poorly understood31. Mice lacking DUSP2 present a phenotype of reduced inflammatory responses in the ‘K/BxN’ model of rheumatoid arthritis32. However, these effects are difficult to reconcile with observed changes in the activities of the classical MAPK pathways when analysed in DUSP2 knockout cells and tissues. Thus far the possible role(s) of ERK3 and ERK4 signalling in the immune system and inflammation have not been widely explored although recent work suggests that ERK3 plays some role in thymocyte survival and positive selection33,34,35. The discovery that ERK3 and ERK4 may be regulatory targets for DUSP2 in vivo should prompt future studies that may link ERK3 and ERK4 with these inflammatory endpoints and lead to a fuller understanding of the DUSP2 knockout phenotype.
All chemicals were purchased from SigmaAldrich.
The polyclonal antibody against DUSP2 was raised in sheep using recombinant GST-DUSP2 as an antigen. The polyclonal antibodies against ERK4 and MK5 phosphorylated at threonine 182 have been described previously6,23 and were kindly provided by Philip Cohen (MRC protein phosphorylation Unit, Dundee, UK). The polyclonal GFP antibody (sc-8334) and a polyclonal GST (Z-5) antibody (sc-459) were purchased from Santa-Cruz Biotechnology (Santa Cruz, CA). The monoclonal ERK3 antibody (clone 4C11) was purchased from Abnova (Taiwan). Anti-FLAG (M2-conjugated) was purchased from Sigma-Aldrich. The polyclonal antibody recognizing ERK3 phosphorylated at Serine 189 (AP3098a) was purchased from Abgent (San Diego, Ca, USA). Monoclonal anti-myc antibody (9E10) was from Cancer Research-UK. The rabbit polyclonal anti-EGFP antibody used for immunoprecipitation of EGFP fusion proteins was kindly provided by T. Johansen (University of Tromsoe). Alexa Fluor® 680 goat anti-rabbit IgG (A21076), Alexa Fluor® 680 goat anti-mouse IgG (A-21057) and Alexa Fluor® 680 donkey anti-sheep IgG (A-21102) were purchased from Life technologies. IRDye 800 conjugated anti-HA (glutathione transferase) (600-132-200) and anti-Myc antibodies (600-132-215), IRDye 800CW conjugated affinity-purified anti-mouse IgG (610-131-121) and IRDye 800CW conjugated affinity-purified anti-rabbit IgG (611-131-122) were purchased from Rockland. Monoclonal Anti-CD3 antibody (#555329) was purchased from BD Bioscience.
HeLa cells (ATCC CCL2) were maintained in Eagle’s minimum essential medium supplemented with 1x nonessential amino acids (Invitrogen), 10% fetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100μg/ml). HEK 293 cells (ATCC CRL-11268) were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100μg/ml). NCI-H1299 cells (ATCC CRL 5803) were maintained in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100μg/ml). Jurkat E6.1 cells (ATCC TIB152) were maintained in RPMI 1640 containing 10% FBS. Lipofectamine Plus (Invitrogen) reagent was used to transfect the cells according to the manufacturer’s instructions. Jurkat cells were transfected using Amaxa nucleofection (Lonza Group Ltd) according to the manufacturer’s protocol.
To generate pGEX-mDUSP2, full-length mDUSP2 was amplified by PCR from an EST-clone and inserted into the NdeI/XhoI sites of pGEX-5X-3 (GE-Healthcare) using the following PCR primers 5′-gaggaattcatatggggctggagacggcgtgcgag-3′ and 5′-ccgctcgagtcagtgacacagcacctgggtctg-3′. pGEX-mDUSP2CS was generated by site-directed mutagenesis using the Quickchange method (Stratagene) and the primer (only forward shown) 5′-gggccgggtgctggtgcacagccaagctggcatctctcgc-3′. To make a kinase interaction motif (KIM)-deficient version of pGEX-mDUSP2 (pGEX-mDUSP2KIM), a construct encoding a protein where three subsequent arginine residues at position 60, 61 and 62 were replaced by alanine, serine and alanine, respectively, was generated by site-directed mutagenesis using primer 5′-ccctggaacgcgctgctggcgtcggctgcgcgcggcacccccgcc-3′ (forward). For expression epitope-tagged DUSP2 in mammalian cells human DUSP2 was amplified using the following primers; 5′-gaggaattcatatggggctggaggcggcgcgcgag -3′ and 5′-ccgctcgaggtgacacagcacctgggtctc-3′ and subcloned as a EcoRI/XhoI fragment into a modified pSG5 vector encoding either a single Myc-tag or HA-tag at the C-terminus of the expressed protein. The expression constructs for EGFP-MK5, epitope-tagged p38α and JNK-1, epitope-tagged wild-type and mutant forms of ERK2, ERK3, and ERK4 have been described earlier8,14,22,23,36
Expression plasmids encoding GAL4 DB (DNA-binding domain) and AD (activation domain) fusion proteins were transformed into the Saccharomyces cerevisiae strains PJ69-2A(MATa) and Y187(MATα) respectively, using the Frozen-EZ Yeast Transformation II (Zymo Research), and plated out on to suitable drop-out medium, according to the manufacturer′s protocol. The yeast-mating procedure and semi-quantitative β-galactosidase assay were performed as described previously14.
GST fusion proteins of wild-type and mutants of murine DUSP2 were expressed in E.coli (BL21) by induction with 0.1mM isopropyl-1-thio-β-D-galactopyranoside at 18°C for 20h (overnight) and purified using glutathione-sepharose using standard techniques. SDS PAGE and Coomassie Blue staining were used to analyze both the expression and yield of the fusion proteins.
2μg recombinant ERK4 and ERK3 were precleared prior to the pull-down using 2μg GST-protein and 30μl Glutathione-Sepharose (Amersham Biosciences AB) (50% slurry equilibrated in a buffer containing 50mM Tris/HCl pH 7.5, 1mM EGTA, 1mM EDTA, 1% (w/v) Triton-X 100, 1mM sodium orthovanadate, 50mM sodium fluoride, 5mM sodium pyrophosphate and 0.27M sucrose) for 1h at 4°C. Direct interaction between DUSP2 and the atypical MAP kinases was detected by incubating 2μg of recombinant ERK4 or ERK3 with 2μg purified GST-DUSP2, GST-DUSP2KIM, GST-DUSP2CS or GST in 200μl of the above buffer for 2h at 4°C. After addition of 30μl Glutathione-Sepharose (50% slurry equilibrated in the above buffer) the samples were incubated for an additional hour. The beads were washed 5 times with the above buffer and once in 50mM Tris PH 7.5 and then resuspended in 40μl 2 x SDS-sample buffer. GST-DUSP2 fusions and co-precipitated ERK4 and ERK3 were detected by SDS PAGE and Western blotting using GST antibody and ERK4 or ERK3 antibodies respectively.
Immuno precipitation and co-immuno precipitation of both endogenous and epitope-tagged proteins were performed as previously described23.
For detection of endogenous ERK3, ERK4 and epitope-tagged DUSP2, ERK3, ERK4, and MK5 in transfected cells and co-immunoprecipitation experiments, the samples were analyzed by SDS-PAGE (4–12% NUPAGE, Life Technologies), transferred to a nitrocellulose membrane (Amersham Biosciences), and probed with either anti-ERK3 (1:500), anti-ERK4 (1:1000), anti-Myc (1:200), anti-HA (1:1000), anti-ERK4 (1:1000), anti-P-T182-MK5 (1:500), anti-EGFP (1:200), anti-S186-ERK4 (1:500), anti-phospho-S189-ERK3 (1:500) anti-DUSP2 (1:2000) or anti-GFP IRDyeTM 800-conjugated (1:5000) antibodies. Detection and quantification were performed either directly using anti-GFP IRDyeTM 800-conjugated antibody or by conjugated goat anti-mouse IgG (H&L) or IRDye 800CW-conjugated goat anti-rabbit IgG (H&L) (1:5000) or Alexa Fluor 680-conjugated donkey anti-sheep IgG (H&L) (1:5000) Protein bands were visualized using a Li-Cor Odyssey infrared imager and Immunoblots are representative of three independent experiments. Protein molecular mass was estimated using the MagicMark Western protein standard (Life technologies). Unprocessed original scans of blots are shown in Supplementary Fig. 1.
The phosphatase activity of recombinant murine DUSP2 in the absence or presence of recombinant ERK2, ERK3, or ERK4 was determined by measuring the conversion of para-Nitrophenyl Phosphate (p-NPP) to para-Nitrophenol in a spectrophotometric assay. 10μg of GST-DUSP2, GST-DUSP2KIM, GST-DUSP2CS or GST were transferred to 96 Well microtiter plates with or without 10μg ERK2, ERK3, or ERK4. 20mM p-NPP in 200μl buffer containing 50mM imidazole and 10mM dithiothreitol was added per well and the absorbance at 405nm was measured immediately. The plates were then incubated at 23°C in the dark for 3h, and the absorbance at 405nm was measured every 20minutes.
Determination of the subcellular localization of GFP fusion proteins, Myc-tagged DUSP2 and the visualization of cell nuclei was performed as described previously22. Images were collected using a Zeiss LSM510 confocal laser-scanning microscope and processed using Adobe Photoshop. For cell counting experiments several fields of cells from each transfection or co-transfection were examined and at least one hundred cells were scored for the subcellular localization of the protein(s) of interest.
How to cite this article: Perander, M. et al. Regulation of atypical MAP kinases ERK3 and ERK4 by the phosphatase DUSP2. Sci. Rep. 7, 43471; doi: 10.1038/srep43471 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We are grateful to Prof. Philip Cohen and the protein production and antibody purification teams [Division of Signal Transduction Therapy (DSTT), University of Dundee] co-coordinated by Hilary McLauchlan and James Hastie and Prof. Terje Johansen (University of Tromsoe) for antibodies. The work was supported by The National Programme for Research in Functional Genomics in Norway (FUGE) of The Research Council of Norway, the Norwegian Cancer Society, the Blix Family Foundation, Northern Norway Regional Health Authority/Helse Nord RHF and the Aakre foundation (to O.M.S). Research in the Stress Response Laboratory is supported by Cancer Research UK Program Grant C8227/A12053 (to S. M. K.).
The authors declare no competing financial interests.
Author Contributions M.P., R.A.M., B.J. S.M.K. and O.-M.S., designed research; M.P., R.A.M., H.K., B.J., M.G., J.A.L.N, T.C.J. and O.-M.S. performed research;. M.P., R.A.M., H.K., B.J., M.G. J.A.L.N, T.C.J., S.M.K. and O.-M.S. analyzed data; and M.P., S.M.K. and O.-M.S. wrote the paper.